Stockscreener 앱 받기
27.54
1.04%
-0.29
시간 외 거래:
27.54
전일 마감가:
$27.83
열려 있는:
$27.99
하루 거래량:
1.53M
Relative Volume:
0.85
시가총액:
$2.60B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-4.2566
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
-3.16%
1개월 성능:
-30.14%
6개월 성능:
-39.27%
1년 성능:
-45.24%
1일 변동 폭
$27.40
$28.21
1주일 범위
$26.52
$29.15
52주 변동 폭
$25.81
$60.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
27.54 | 2.70B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - FinancialContent
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersHigh Conviction Stock Long-Term Summary - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - uk.finance.yahoo.com
Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights - AInvest
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyEquity Portfolio Outlook and Performance Summary - Newser
FDA requests manufacturing changes for UX111 gene therapy - Sanfilippo Syndrome News
Ultragenyx Bets On Growth With Bullish Analyst Backing - Finimize
Ultragenyx Pharmaceutical Q2 2025 Earnings: Revenue Beats Expectations, Loss Narrows - AInvest
Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
‘Urgent need’ for treatment drives GTX-102 study enrollment - Angelman Syndrome News
Ultragenyx Pharmaceutical Inc. stock momentum explainedFree Proven Entry Plan With Low Risk Trade - Newser
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges - TipRanks
‘On track to become profitable’: Marin County rare disorder drug maker narrows loss in Q2 - The North Bay Business Journal
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ultragenyx (RARE) Q2 Revenue Up 13% - Nasdaq
Ultragenyx Pharmaceutical Inc. SEC 10-Q Report - TradingView
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
Ultragenyx outlines $640M–$670M 2025 revenue target as clinical milestones advance - MSN
Ultragenyx: Q2 Earnings Snapshot - New Haven Register
Price action breakdown for Ultragenyx Pharmaceutical Inc.Long Term Equity Screener with Safety Metrics - Newser
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Ultragenyx Pharmaceuticals: A High-Stakes Play in Rare Disease Gene Therapy - AInvest
Ultragenyx's Q2 2025 Earnings Call: Dissecting Contradictions on Setrusumab Efficacy, FDA Interactions, and Resubmission Strategy - AInvest
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript: Financial Results and Business Update - AInvest
Ultragenyx Sets 2025 Revenue Target at $640M-$670M Amid Clinical Advancements - AInvest
Ultragenyx Reports Growth Amidst Strategic Advancements - TipRanks
Earnings call transcript: Ultragenyx Q2 2025 beats EPS forecast, stock rises - Investing.com
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - sg.finance.yahoo.com
Ultragenyx Reports Better-Than-Expected Q2 Loss and RevenueNews and Statistics - IndexBox
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ultragenyx August 2025 slides: Pipeline advances toward approvals as revenue grows By Investing.com - Investing.com South Africa
RENEW 8-K: Ninth SPAC Extension Adds $250k to Trust, Deadline Sep 5 2025 | RARE SEC FilingForm 8-K - Stock Titan
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockLow Risk Stock Selection Strategy Guide - Newser
Visual trend scoring systems applied to Ultragenyx Pharmaceutical Inc.RSI and MACD Signal Summary with Trends - Newser
Ultragenyx Pharmaceutical Earnings Report: Analysts Expect $-1.31 EPS, Shares Down 42.98% Over Last Year - AInvest
Ultragenyx Pharmaceutical's Promising Outlook: Buy Rating Reiterated Amidst Aspire Study Progress - AInvest
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory - Insider Monkey
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome - MSN
What to Expect From Ultragenyx Pharmaceutical's Earnings - 富途牛牛
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):